Advice
following a full submission:
rituximab (MabThera®) is accepted for restricted use within NHS Scotland.
Indication under review: Rituximab maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
SMC restriction: for maintenance treatment in follicular lymphoma patients who have responded to induction with rituximab plus chemotherapy.
Rituximab significantly increased progression free survival following a response to induction therapy in patients with previously untreated follicular lymphoma compared with observation alone. Longer follow up is required to establish benefit in overall survival.
Download detailed advice111KB (PDF)
Medicine details
- Medicine name:
- rituximab (Mabthera)
- SMC ID:
- 675/11
- Indication:
- Follicular lymphoma patients responding to induction therapy
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 February 2011